Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif. – June 5, 2025 – (BUSINESS WIRE) Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company’s proprietary low-dose atropine formulation, for slowing the […]
FDA Grants Atia Vision Approval to Begin US Clinical Trial of OmniVu™ Lens System in Patients with Cataracts
The OmniVu is arevolutionary dual-optic lens designed to restore dynamic visual function by harnessing the eye’s natural accommodative mechanism while preserving its anatomical integrity. Global clinical trials show promising long-term predictability and stability in more than 75 treated eyes. CAMPBELL, Calif.–(BUSINESS WIRE)–Atia Vision, Inc., a Shifamed portfolio company, today announced it has received Investigational Device […]
Julius Clinical and Peachtree BioResearch Solutions Merge to Form a Fully Integrated Global CRO with Increased CNS Capabilities
Zeist, Netherlands, May 14, 2025– Julius Clinical, a leading full-service Contract Research Organization (CRO) headquartered in the Netherlands (Zeist), and Peachtree BioResearch Solutions, a specialized CNS CRO based in the United States (Georgia), announce they have merged as a fully integrated clinical research organization. The merger combines scientific and operational excellence, an expanded international footprint […]
Sydnexis Announces Three Abstracts Accepted for Poster Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
DEL MAR, Calif. – Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company, announces that three abstracts have been accepted for poster presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting taking place from May 4 to 8 in Salt Lake City, UT. These posters present clinical data related to the […]
Sydnexis Announces Positive CHMP Opinion in Europe for SYD-101 for Slowing the
ProgressSanten is Sydnexis’ Licensing Partner to Commercialize SYD-101 within the EMEA Region upon issuance of a Marketing Authorization by the European Commission DEL MAR, Calif. – April 1, 2025 – Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has […]
Sydnexis Announces FDA Acceptance of New Drug Application for SYD-101 for the Treatment of Progression of Pediatric Myopia
DEL MAR, Calif. – March 11, 2025 – Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for SYD-101 and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 23, 2025. If approved, SYD-101 […]
TECLens Secures $9.3 Million Series A Funding to Advance Its Non-Invasive Refractive Technology
STAMFORD, Connecticut – February 11, 2025 – TECLens, Inc., a clinical-stage ophthalmic medical device company, announced today it raised $9.3 million in a Series A round co-led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital. Other investors include Rimonci Capital, and Sunmed Capital. The funding is allocated to support the clinical development […]
Centricity Vision to Introduce New ZEPTOLink Enhancements Boosting the Platform Efficiency and Control at the American Academy of Ophthalmology (AAO) Annual Meeting 2024 CARLSBAD, California – October 15, 2024 – Centricity Vision Inc., a global, commercial-stage ophthalmic technology company, today announced new platform enhancements for the ZEPTOLink IOL Positioning System™ which now enables surgeons […]
Osheru Secures $4.7 Million Seed Funding to Advance Revolutionary Ziplyft Device for Blepharoplasty Surgery
Read full article here: https://www.businesswire.com/news/home/20240723044165/en/Osheru-Secures-%244.7-Million-Seed-Funding-to-Advance-Revolutionary-Ziplyft-Device-for-Blepharoplasty-Surgery
Perry J. Sternberg Joins Sydnexis as Chief Executive Officer
Read full article here: https://www.businesswire.com/news/home/20240716166625/en/Perry-J.-Sternberg-Joins-Sydnexis-as-Chief-Executive-Officer
